Advertisements

Neosaldina

Quick links to important sections

Neosaldina

Advertisements
Advertisements

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Neosaldina

Quick Facts

Property Description
Active Ingredients Metamizole (Dipyrone), Caffeine, Isometheptene Mucate
Form Oral Solid (Tablet or Capsule)
Pharmacological Class Non-Opioid Analgesic, Antipyretic, and Sympathomimetic Combination
Common Purpose Relief of Acute Pain and Fever
Origin Synthetic Chemical Compounds

What Type of Medicine is Neosaldina?

Neosaldina is definitively classified as a fixed-dose combination product belonging to the non-opioid analgesic and antipyretic pharmacological class. This structure, which utilizes an oral solid form (tablet or capsule), integrates three distinct synthetic active ingredients. Unlike most single-entity pain relievers, which operate through one primary action, Neosaldina's design is inherently a multi-component therapy, distinguished by its strategic inclusion of agents that target multiple pain-related pathways simultaneously. This specific three-part formulation is designed for general symptomatic relief.

Composition: Why Does Neosaldina Have Three Ingredients?

The medication relies on the complementary actions of its three components: Metamizole (Dipyrone), Caffeine, and Isometheptene (as the mucate salt). Metamizole acts as the core agent, providing potent analgesic and antipyretic action. Isometheptene is included for its ability to affect vascular tone by inducing vasoconstriction, which targets a physiological component of some pain types. Caffeine functions as an adjuvant to enhance the analgesic effect and optimize its overall speed. This synergistic action is the core rationale for the combination, aiming to provide a broader and more comprehensive therapeutic response than the individual ingredients.

Neosaldina’s General Therapeutic Purpose

The general therapeutic purpose of Neosaldina is the effective and comprehensive management of acute pain, particularly various forms of headache, and associated elevated body temperature. Due to its combination of analgesic, antipyretic, and vascular-regulating mechanisms, the drug is typically used when pain relief requires addressing more than just the signal. This multi-pathway strategy is intended to provide a robust and multi-pathway approach to pain signal management, offering patients an efficient and targeted response to discomfort.

Regulatory References

  1. PubChem NIH, Isometheptene Mucate CID 15605556
Advertisements

What side effects are possible with Neosaldina?

Possible Side Effects and Safety Information

The official regulatory safety profile for this medicine is based primarily on the risks documented for its core component, Metamizole (Dipyrone), focusing on rare but serious adverse reactions. The combination of active ingredients results in effects across multiple system-organ classes.


Serious and Rare Adverse Reactions

The most significant risks documented by regulatory authorities involve the Blood and Lymphatic System, including the rare potential for agranulocytosis and aplastic anaemia. These conditions, which affect white and red blood cell production, can occur at any time during or shortly after treatment and are not related to the dose used. Severe allergic reactions, such as anaphylactic shock, and severe skin disorders like Stevens-Johnson syndrome are also documented as rare adverse events.


Common Adverse Reactions and Systemic Effects

Adverse effects classified as common include effects on the Gastrointestinal and Nervous Systems, such as nausea, vomiting, dizziness, and headache. Effects on the Cardiovascular System, including palpitations and hypotension, are also listed, related to both the Metamizole and Isometheptene components.


Population-Specific Safety Constraints

Official labeling defines specific constraints for use. The medicine is contraindicated during the third trimester of pregnancy due to potential risks to the fetus. It is also restricted in patients with pre-existing conditions such as severe hepatic or renal dysfunction, a history of agranulocytosis related to pyrazolones, or specific cardiovascular conditions like severe hypertension or organic heart disease.

Advertisements

Overdose and Emergency Response

The official regulatory profile for this combination product (Metamizole, Caffeine, Isometheptene Mucate) defines overdose risk through a combination of hematological, CNS, and cardiovascular toxicities, all of which require immediate medical attention.

Documented Overdose Manifestations

Overdose presentations officially listed include gastrointestinal toxicity (nausea, vomiting, abdominal pain), and signs of CNS excitation, such as confusion, agitation, hallucinations, and convulsions (seizures). Cardiovascular signs are documented as tachycardia, irregular heart rhythm (arrhythmias), and initial hypertension potentially leading to shock. Life-threatening outcomes documented in official prescribing information include acute liver failure, acute kidney injury, and malignant cardiac arrhythmias. A critical, non-dose-related risk is agranulocytosis (a sharp decrease in white blood cells).

When Immediate Medical Help is Required

Regulators mandate that immediate medical attention must be sought for any suspected overdose. Patients must stop the medication immediately and seek urgent medical assistance if specific symptoms suggesting agranulocytosis appear, such as fever, chills, sore throat, or painful mucosal sores. Treatment is restricted to symptomatic and supportive measures, as no specific antidote is known for the primary components. Management procedures include gastrointestinal decontamination (e.g., activated charcoal) and required hospital monitoring of vital signs, heart rhythm (ECG), and immediate blood cell counts.

Advertisements

Therapeutic Uses of Neosaldina

What Neosaldina Treats: Main Uses and Benefits

Neosaldina is used for the symptomatic relief of symptoms related to physical discomfort across several therapeutic domains. It is commonly used across conditions characterized by episodic or suddenly intensifying symptom patterns. The core analgesic component, Metamizole (Dipyrone), is utilized for its properties related to the management of pain, fever, and spasm. This multi-component product provides supportive assistance to help ease the overall burden of challenging manifestations.

The medication is generally applied in contexts where short-term symptomatic assistance is needed, relevant for easing symptoms related to acute head pain, including tension-type headaches and migraine attacks, as well as pain associated with smooth muscle spasms and colic. It is also commonly used to manage systemic febrile symptoms and elevated body temperature.

“The combined formulation supports the patient during difficult episodes by helping ease the discomfort stemming from multiple symptom axes.”

The therapeutic benefit is to offer support that helps patients cope more steadily with difficult episodes, and assists with maintaining functional stability when symptoms are more noticeable.

Overview: Symptom Management
Therapeutic Area Acute pain and headache relief
Ancillary Use Management of spasms and fever
Clinical Context Episodic and acute symptom flares

Regulatory References

  1. NIH LiverTox overview of Metamizole
Advertisements

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Official regulatory documentation establishes strict rules governing who can and cannot use Neosaldina, primarily due to the presence of Metamizole (Dipyrone).

Population Status Eligibility Restrictions (Formal Contraindications)
Allergy/Hypersensitivity Individuals with known allergy or intolerance to any component (Metamizole, Isometheptene, Caffeine), other pyrazolones (e.g., phenazone), or pyrazolidines. This includes a prior history of anaphylactic-type reactions (like bronchospasm or hives) to other common analgesics (Aspirin, NSAIDs, Paracetamol).
Hematologic Status Patients with a history of Metamizole-induced agranulocytosis, impaired bone marrow function, or pre-existing diseases of the hematopoietic system (blood-forming system).
Metabolic Disorders Individuals with acute intermittent porphyria or a congenital deficiency of glucose-6-phosphate dehydrogenase (G6PD).
Cardiovascular/Systemic Patients experiencing crises of arterial hypertension (severe high blood pressure) or severe organic heart disease.
Physiological Status Pregnant women (especially in the third trimester) and lactating/nursing women must not use this medicine.
Age Profile Contraindicated for infants under 3 months of age or weighing less than 5 kg. The combination product (tablets) is typically restricted for use in children under 12 years.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Neosaldina is a fixed-dose combination product containing Metamizole (Dipyrone), Isometheptene Mucate, and Anhydrous Caffeine. Its interaction profile requires careful review of co-administered medications.

Medications and Substances to Avoid

Co-administration is contraindicated with alcoholic beverages, as Metamizole may potentiate the effects of alcohol. Avoid concurrent use with Cyclosporine and Chlorpromazine (risk of severe hypothermia).

Pharmacokinetic and Pharmacodynamic Interactions

Metamizole can act as a hepatic enzyme inducer (specifically CYP2B6 and CYP3A4), potentially reducing the plasma concentration and efficacy of co-administered drugs that are substrates for these enzymes. Examples include Bupropion, Sertraline, Efavirenz, Tacrolimus, and Methadone.

Simultaneous use with low-dose Aspirin (acetylsalicylic acid) may inhibit its antiplatelet effect, necessitating careful timing of administration.

Monoamine Oxidase Inhibitors (MAOIs) should be avoided due to the potential for hypertensive reactions arising from the Isometheptene and Caffeine content. Caffeine may also reduce the sedative effect of anxiolytics/benzodiazepines.

Patients taking oral anticoagulants, lithium, or antihypertensives require cautious use and monitoring. The reliability of oral contraceptives may be decreased, requiring a warning to the patient.

Advertisements

Mechanism of Action

Mechanism of Action

The physiological effect of this combination drug is achieved through three distinct mechanistic domains. The first component, Metamizole (dipyrone), acts as an inhibitor primarily within the Central Nervous System (CNS), modulating Cyclooxygenase (COX) enzyme activity. This leads to a reduction in the synthesis of prostaglandins, which are key mediators in regulating central nervous system sensitivity. The resulting molecular action diminishes the signal intensity within central nociceptive pathways.

Simultaneously, Isometheptene mucate functions as an agonist at alpha-adrenergic receptors located on vascular smooth muscle, particularly in extracranial vessels. This interaction triggers vasoconstriction, thereby influencing the regulation of vascular tone and modifying blood vessel diameter. The third component, Caffeine, acts as an antagonist at adenosine receptors in the CNS, increasing neuronal activity and stimulating neurotransmitter release. This mechanism engages pathways that increase central nervous system arousal, collectively contributing to the overall physiological modulation of the drug’s components.

Advertisements

Dosage and Administration Information

The administration of Neosaldina follows standardized parameters for this fixed-dose combination (Metamizole/Isometheptene/Caffeine). The medicine is for oral administration, available in a Coated Tablet (Drágea) and an Oral Solution (Gotas) form.

The dosing schedule is structured for acute, intermittent use, meaning the medicine is taken as needed rather than on a continuous, maintenance basis. For adults, the described single dose for the coated tablet form is one to two tablets, with a subsequent dose permitted only after a minimum 6-hour interval. There is a strict maximum limit of 8 coated tablets within a 24-hour period.

Specific administration conditions apply to each formulation. The coated tablet is designed to be swallowed whole and must not be split, chewed, or crushed. The oral solution should be measured and administered via a spoon, never directly into the mouth. The use of higher doses or administration over a prolonged duration is intended only under the explicit recommendation of a health professional.

High-level population-specific use rules are established. The coated tablet formulation is not indicated for individuals under 12 years of age. Furthermore, special consideration is given to older adults, who are generally advised to receive smaller doses and avoid nocturnal use. Patients with existing hepatic or renal impairment are directed to avoid high doses or extended periods of administration to limit systemic exposure. Should a scheduled dose be missed, the instruction is to maintain the minimum 6-hour interval before taking the next dose, with a strict prohibition on taking a double dose.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Neosaldina

The understanding of how the fixed-dose combination product of Metamizole, Isometheptene, and Caffeine is applied in research was studied for structured clinical research, primarily focusing on acute symptom management. Studies in this area utilize methods like controlled trials to explore the patterns of change observed in defined groups of people.


Evidence from Controlled Trials for Acute Headache Relief

Research evidence for the combination product includes randomized controlled trials (RCTs). This design is highly relevant in trials assessing short-term or episodic symptom patterns because it is used in research exploring how symptoms change over time by comparing the study product to an inactive placebo or to an active comparator. The research examined how symptoms evolved in adult patients experiencing acute episodes of primary headache disorders, including mild-to-moderate tension-type headache and certain forms of migraine.

In these studies conducted during periods of increased symptom activity, the researchers aimed to measure several specific outcomes related to physical discomfort. The studies explored what proportion of participants achieved the Sustained Pain-Free (SPF) rate. This SPF measurement is one way researchers monitored outcomes describing episodic or acute changes, defined as being headache-free at a specific time point (such as two hours) and not needing additional pain medication for the next 24 hours.

Findings describe patterns observed in the studies related to outcomes related to physical discomfort. Studies examined the difference in the SPF rate between the group receiving the combination and the group receiving placebo. Studies also explored patterns of pain severity change when comparing the combination product to an active comparator.

How Researchers Measured Treatment Success

Studies focused on episodes where symptoms become more noticeable, measuring success based on patient-reported outcomes describing perceived discomfort. Beyond the Sustained Pain-Free rate, researchers routinely examined pain severity using scales at intervals like 30, 90, and 120 minutes to see how symptoms evolved in the observed populations. Furthermore, research monitored the requirement for rescue medication use as an outcome reflecting daily functioning or activity level. The overall aim of this research was to understand symptom patterns and contribute to the broader evidence landscape.


Long-term Follow-up and Durability of Response

Research exploring short-term symptom changes is primarily what is available for this combination product. The follow-up durations were limited, as the studies focus on acute or disruptive episodes. For instance, the main Sustained Pain-Free endpoint was observed in responses over a defined time interval of 24 hours.

Due to this focus, long-term effects are not fully established. The evidence is limited regarding the use of the combination product over extended periods, and studies monitoring effects beyond the initial day of treatment are less prevalent. There is limited information for long-term outcomes related to repeated use or durability of symptom control over weeks or months.


Evidence in Specific Patient Groups and Sub-Populations

The results apply only to the populations studied: adults between 18 and 65 years old who presented with headaches where symptoms may vary in intensity but were defined as mild to moderate at the time of the trial.

However, data for certain groups remain insufficient. Research provides context but not individual predictions for populations outside of this core group. Specifically, data for certain groups remain insufficient for long-term outcomes or initial evaluation in older adults or in children. Comparative evidence is lacking for how this combination may be applied in conditions marked by functional limitations alongside major comorbidities.


What Remains Uncertain in the Research Landscape

Evidence highlights what is known—and what is still uncertain—about this fixed-dose combination. The research provides insight into short-term changes for conditions involving periods of heightened symptoms, but the certainty remains low for several areas. For example, the evidence is limited regarding its use in the most severe headache attacks, as the studies mainly included patients with mild-to-moderate pain. Furthermore, while research provides insight into short-term changes, data are still emerging regarding the appropriate research contexts for using this fixed combination in conditions presenting with cycles of stability and flare-ups. Comparative evidence is lacking in several areas that might help contextualize how patients reported their experience across different groups or treatment schedules.

Key Studies & References

  1. Efficacy and safety of the combination of dipyrone, isometheptene mucate, and caffeine versus paracetamol and placebo in the acute treatment of primary headaches: a phase IV, randomized, double-blind, crossover study
  2. A Study to Describe Pain Intensity, Pain Relief and Safety of Neosaldina in the Treatment of Tension-Type Headache (TTH)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Neosaldina (FAQ)


Q: How quickly does Neosaldina start to work?

A: The core active ingredient, Metamizole, is known to be rapidly absorbed by the body after it is taken orally. Although official documents for the specific combination product do not define an exact time to the onset of action, research for the main component often notes a noticeable effect around 30 minutes after administration by injection. A specific onset time for pain relief from the oral combination product is generally not defined in regulatory overviews, and individual response may vary.


Q: How long do the effects of Neosaldina usually last?

A: Regulatory documents use official dosing schedules to standardize safe use. These schedules typically permit a subsequent dose only after a minimum interval of six to eight hours. This interval is used to standardize the frequency of administration but is not defined as the exact duration of action for an individual dose.


Q: Can Neosaldina cause drowsiness or make you sleepy?

A: Yes, official safety profiles list effects on the Central Nervous System. These documents indicate that common adverse events associated with the main ingredient, Metamizole, can include somnolence, which is the medical term for drowsiness or sleepiness. The potential for this effect is part of the officially documented safety profile.


Q: Is it normal to feel dizzy after taking Neosaldina?

A: Feeling dizzy, medically referred to as vertigo, is a possibility when using this medicine. Official safety information for the main component, Metamizole, lists dizziness as a common adverse event. This means that a noticeable number of people in studies have reported experiencing this effect.


Q: Does Neosaldina interact with alcohol?

A: Official product information strictly advises against the co-administration of this medicine with alcohol. Regulatory documents state that the core ingredient, Metamizole, may enhance or potentiate the effects of alcohol.


Q: Does Neosaldina have a listed effect on mental alertness?

A: The medicine is a combination product that includes Caffeine, which is classified as an antagonist at adenosine receptors in the Central Nervous System (CNS). This mechanism is associated with increasing neuronal activity and stimulating CNS arousal.


Q: Is Neosaldina the same as Novalgin?

A: Novalgin is a widely known trade name for the single-ingredient drug Metamizole (Dipyrone). Neosaldina is not the same, as it is a fixed-dose combination product. It contains Metamizole along with two other active ingredients, Caffeine and Isometheptene, to address multiple pain pathways.


Q: Is Neosaldina an anti-inflammatory drug?

A: The core active ingredient, Metamizole, is primarily classified as an analgesic (pain reliever) and antipyretic (fever reducer). While some regulatory sources classify it as having weak non-steroidal anti-inflammatory drug (NSAID) properties, its main reported action is distinct and centralized, providing relief largely independent of anti-inflammatory effects.


Q: Are there any specific foods or drinks that should be avoided when using Neosaldina?

A: Official product information generally advises caution regarding alcoholic beverages. Beyond this warning, specific foods or non-alcoholic drinks are not routinely listed in regulatory documents as needing avoidance.


Q: Can Neosaldina affect birth control pills?

A: Yes, official product information includes a warning about this interaction. Regulatory documents state that the primary ingredient, Metamizole, may decrease the reliability of oral contraceptives (birth control pills).


Q: Is Neosaldina available without a prescription?

A: The availability of this medicine, including its over-the-counter or prescription status, depends entirely on the specific country's governing regulatory body. The active ingredient, Metamizole, is available without a prescription in some countries but is restricted in others.


Q: What is the maximum number of days Neosaldina should be used consecutively?

A: Regulatory documents describe the medicine's approved context as short-term use for managing acute symptoms. Some official regulatory guidelines advise restricting continuous use to a maximum of a few days, such as two to five days, when taking it for acute pain indications.


Q: Can Neosaldina be used for dental pain relief?

A: The primary component, Metamizole, is officially indicated for the relief of various origins of acute and intense pain. While the active ingredient is officially indicated for the relief of various origins of acute and intense pain, dental pain is not always explicitly listed as a primary indication.


Q: Can Neosaldina be crushed or divided, based on its formulation?

A: Official regulatory guidance regarding the coated tablet formulation is very specific. It states that the tablet is designed to be swallowed whole and must not be split, chewed, or crushed.


Q: Is it possible for Neosaldina to cause a rebound headache?

A: Official sources on headache management indicate that the regular, long-term use of combined painkillers for more than a set number of days per month can be associated with the development of Medication Overuse Headaches. These are sometimes referred to by users as 'rebound headaches.'


Q: What should a patient do if they experience a severe side effect?

A: Official patient guidance states that symptoms suggestive of severe adverse events, such as a high fever or painful changes in the mouth or throat (suggesting a serious blood disorder), require the medicine to be discontinued immediately and that immediate medical attention should be sought.


Q: Does Neosaldina interact with psychiatric medications?

A: Yes, the official product information lists interactions with certain medications often used in psychiatric contexts. For example, the drug may interact with Bupropion and Sertraline by potentially reducing their concentration in the body, which could decrease their efficacy.


Q: What is the mechanism of action of the muscle relaxant component in Neosaldina?

A: The component Isometheptene is classified as a sympathomimetic amine that influences blood vessel tension. Its primary mechanism is to cause vasoconstriction (narrowing of blood vessels) by interacting with specific receptors, which helps regulate vascular tone rather than directly relaxing skeletal muscle.


Q: Is Neosaldina used to treat fevers?

A: Yes, the medicine is officially classified as an antipyretic, which means it has fever-reducing properties. It is indicated for managing associated elevated body temperature alongside its use for pain relief.

Advertisements

How should Neosaldina be stored and disposed of?

How to Store and Dispose of Neosaldina?

Storage Requirements

Neosaldina must be conserved at room temperature, specifically between 15°C and 30°C. The product must be kept in its original packaging and always maintained outside of the sight and reach of children. Certain formulations require additional protection from both light and humidity. Using the medicine after its labeled expiration date is prohibited, regardless of storage conditions.

Disposal Instructions

Official guidelines state that unused or expired medicine should not be flushed down a sink or toilet. When a drug take-back program is unavailable, federal recommendations suggest mixing the medicine with an unappealing substance, such as used coffee grounds, and placing the mixture into a sealed container before disposal in the household trash. All identifying information must be removed from the original label before discarding.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Neosaldina found in:

A-Z Index: